ozempic and other glp-1 drugs Ozempic, Wegovy: Why Don't Work for Everyone Ozempic and Other Off-Label Drugs
Description
Tirzepatide, a newer GLP-1/GIP dual agonist, and retatrutide, a triple agonist still in trials, have pushed results even further, with average weight loss approaching 2025% of body weight
Hanna, S., Sethiadi, J., Ali, Q., & Sinha, S
Interested in seeing if Found is right for you
For Metformin, commonly prescribed for PCOS, persistence dropped from 57.7% at three months to just 31.2% at the one-year mark
2024) or tirzepatide (Packer et al, 2025a
Erbil D, Eren CY, Demirel C, Kucuker MU, Solaroglu I, Eser HY
